TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update November 13, 2024
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition November 5, 2024
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 12, 2024
TScan Receives FDA’s Regenerative Medicine Advanced Therapy Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies May 29, 2024
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update May 15, 2024
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors May 10, 2024
